Company intelligence / Profile preview
Novilla Pharmaceuticals
Cambridge, Massachusetts, United Statesnovilla.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Novilla Pharmaceuticals is developing a patented transdermal/topical drug delivery platform aimed at providing effective pain relief without the risks associated with traditional opioid medications. Their approach seeks to minimize systemic exposure and addiction risk by delivering drugs directly to the site of action. As an early-stage company founded in 2019, they are advancing preclinical or possibly early clinical programs targeting pain management.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculeTransdermal technology
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed.
Beyond the preview
Go deeper on Novilla Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novilla Pharmaceuticals.